Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Example of a positive Phase 1/2A news release - AFMD
View:
Post by barsax on Nov 07, 2022 11:11am

Example of a positive Phase 1/2A news release - AFMD

in solid tumors

[url=https://ceo.ca/@globenewswire/affimed-provides-data-update-from-two-phase-12a-trials]AFMD[/url]
Comment by PWIB123 on Nov 07, 2022 11:34am
And the stock is up 24% this morning, 36% over the last week. That update seemed very positive even in early stages and provided much clarity.
Comment by Wino115 on Nov 07, 2022 12:06pm
Yes, and this statement that is the centerpiece of their PR is something THTX has also seen and could justify as much as Affimed did. Similar market caps too. "Initial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary data from the combination study investigating AFM24 administered in combination with the immune checkpoint ...more  
Comment by Biobob on Nov 07, 2022 12:08pm
Where is Beliveau in all this... he's a TV Star in Qc... great communicator...  it's mindbogling...
Comment by qwerty22 on Nov 07, 2022 12:49pm
Nothing to say yet.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities